Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NexImmune, Inc. logo — NexImmune, Directing T cell function to restore natural immu...

NexImmune, Inc.

NexImmune, Directing T cell function to restore natural immunity

Founded 2011 United States Gaithersburg, United States 32 employees Post Ipo Equity Total: $87.44M Biopharma, Biotechnology +1

General Information

Company Name NexImmune, Inc.
Founded Year 2011
Location United States Gaithersburg, United States +1
Employees 32
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when NexImmune, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About NexImmune, Inc.

NexImmune, Inc. is a publicly traded, clinical stage biotechnology company founded in 2011 and is making strides in the development of T cell immunotherapies through its propriety Artificial Immune Modulation (AIM™) technology. The company is focused on addressing unmet medical needs in oncology, specifically targeting relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy with its lead programs. NexImmune's AIM technology allows for the construction of nanoparticles that mimic the function of synthetic dendritic cells, directing a specific T cell-mediated immune response while reducing potential toxicities. This innovative approach offers attributes of cellular precision, potency, and persistence, positioning the company as a disruptive force in the oncology, autoimmune disorders, and infectious disease spaces. In February 2024, NexImmune secured a notable $3.67MPost-IPO Equity investment, signaling investor confidence in the company's technology and pipeline. The investment underscores the potential for therapeutic impact in various therapy targets and reflects the significant adaptability and flexibility of the AIM platform. As the company continues to advance its product candidates through phases of development, it presents an appealing opportunity for venture capital seeking to engage with a forward-thinking player in the biopharma and biotechnology industries. With its innovative platform and promising pipeline, NexImmune's efforts in directing T cell function to restore natural immunity position it as a compelling investment prospect in the evolving landscape of biotechnology and immunotherapy.

Taxonomy: immunotherapy, T cell immunotherapies, cancer treatment, clinical stage, proprietary technology, AIM technology, oncology, autoimmune disorders, pharmaceutical company, immuno-therapeutics, artificial immune modulation, nanoparticles, acute myeloid leukemia, multiple myeloma

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 02 Feb 2024
Convertible Note •••••• 1
Investor
08 Jan 2021
Venture Round •••••• - 22 Feb 2019
Series A •••••• 3
Investor Investor
•••• •••• 		02 Jan 2018
Venture Round •••••• 3
Investor Investor
•••• •••• 		18 Jul 2014

View All 6 Funding Rounds

NexImmune, Inc. Alternatives & Competitors

NexImmune, Inc. vs
Curocell
Curocell Korea South

Fight against hopelessness

Series Unknown
26 employees
Biopharma, Biotechnology
Compare NexImmune, Inc. vs Curocell
NexImmune, Inc. vs
Tolerx, Inc.
Tolerx, Inc. United States

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candi...

Series Unknown
9 employees
Biotechnology, Health Care
Compare NexImmune, Inc. vs Tolerx, Inc.
NexImmune, Inc. vs
Gamida Cell Ltd.
Gamida Cell Ltd. United States

Working to turn cells into powerful therapeutics for patients with cancer.

Post Ipo Debt
93 employees
Biotechnology, Health Care
Compare NexImmune, Inc. vs Gamida Cell Ltd.

FAQ About NexImmune, Inc.

NexImmune, Directing T cell function to restore natural immunity
NexImmune, Inc. was founded in 2011.
NexImmune, Inc. is headquartered in Gaithersburg, United States.
NexImmune, Inc. operates in the following industries: Biopharma, Biotechnology, Health and Wellness.
NexImmune, Inc. has approximately 32 employees.
NexImmune, Inc. has completed 6 funding rounds, raising a total of $87.44M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to NexImmune, Inc. include Curocell, Tolerx, Inc., Gamida Cell Ltd., Huasaiboman Medical Cell Biology, Enlivex Therapeutics (Nasdaq: ENLV). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NexImmune, Inc. and Curocell are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors NexImmune, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy